Global Growth Hormone Deficiency Market Size, Forecast, and Trend Highlights Over 2025-2037
Growth Hormone Deficiency Market size was valued at USD 4.4 billion in 2024 and is projected to reach USD 9.3 billion by the end of 2037, rising at a CAGR of 7.3% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size of GHD is estimated at USD 4.6 billion.
The global growth hormone deficiency market is witnessing tremendous expansion opportunities owing to the rising diagnostic rates, increased applications in pediatric and adult growth hormone disorder treatment. In this context NIH report in 2024 reported that nearly 1.3 million growth hormone deficiency cases are being noted in a year, with pediatric cases holding more than 55% of cases due to congenital and idiopathic causes. This expanding patient pool necessitates the need for appropriate management strategies to mitigate complications in the long run.
Furthermore, the augmentation in the growth hormone deficiency market is appreciably influenced by trade and economic activities. For instance, in 2024, BLS reported that the PPI and CPI of GHD therapeutics increased by 4.5% and 7.4% due to the growing raw material costs and reimbursement delays. Besides, the exports of GHD-associated goods are significantly dominated by the U.S. and EU, with more than 75% of goods. Meanwhile, the imports are led by Brazil and India. Therefore, this is the evidence for a wider market scope with commendable growth opportunities.
Growth Hormone Deficiency Sector: Growth Drivers and Challenges
Growth Drivers
- Emergence of innovative therapies: The major driver of the growth hormone deficiency market is the development of exclusive therapies that aid growth hormone disorders. In this regard, the U.S. FDA reported that Novo Nordisk announced its partnership with 23 hospitals in the U.S. to introduce AI-based dosing tools that boost adherence by 18%. Besides, Pfizer Inc. invested a substantial amount of USD 300.2 million for long-acting GHD formulations, thus creating a positive outlook on the market growth.
- Support from the regulatory frameworks: This is yet another driver for the growth hormone deficiency market, offering extensive policy support. The U.S FDA reported that its orphan drug redesignation accelerated with three new therapies by reducing approval span by 6 months, which is an excellent opportunity for the manufacturers. Besides, in the EU, it is reported that the pharmaceutical strategy aims to reduce approval time by 10 months to attract the interest of global firms to invest in this sector.
Historical Patient Growth and Market Expansion Opportunities for Growth Hormone Deficiency Manufacturers
There is a huge opportunity for the growth hormone deficiency market due to its vast consumer base over the last decade. Due to ongoing innovations in diagnostics, expanded insurance coverage, and awareness of pediatric and adult hormone disorders, the market is witnessing such growth. The emerging markets, such as the U.S., Germany, Japan, and China, experienced increased diagnosis of growth hormone disorders owing to the advancements in neonatal screening, genetic testing, and endocrinology referrals. This contribution from all nations, coupled with the patient growth, is creating an opportunity for the market to expand more.
Below is the tabular breakdown of GHD patient growth in 000s across key markets:
|
Country |
2010 Patients |
2020 Patients |
Key Growth Driver |
|
USA |
47 |
65 |
Medicare Part D expansion |
|
Germany |
20 |
29 |
National screening mandates |
|
France |
14 |
21 |
Pediatric endocrinology investments |
|
Spain |
10 |
15 |
EU orphan drug incentives |
|
Australia |
7 |
11 |
PBS subsidy reforms |
|
Japan |
24 |
37 |
Insurance coverage for adult GHD |
|
India |
11 |
17 |
Urban specialty clinics |
|
China |
27 |
50 |
Tier-1 hospital partnerships |
Manufacturer Strategies and Revenue Potential in the Growth Hormone Deficiency Market
The future of the growth hormone deficiency market relies on the strategies opted for by the key players to diversify their product portfolio. The market expansion is significantly influenced by innovations in biosimilars, geographic expansion, and advanced healthcare technologies. For instance, in 2023, Novo Nordisk launched a next-generation auto injector in Europe, which resulted in a substantial revenue increase of 14%, generating USD 325 million. Besides collaborations and the support from the regulatory frameworks also aids in market upliftment.
Below are revenue opportunities (2023–2025):
|
Company |
Strategy |
Revenue Impact |
Market |
|
Novo Nordisk |
Auto-injector rollout |
+$325M |
EU |
|
Pfizer |
India biosimilar partnership |
+$155M |
India |
|
Eli Lilly |
Long-acting GHD therapy |
+$502M (est.) |
USA |
|
Merck KGaA |
Pediatric formulation expansion |
+$93M |
Latin America |
Challenge
- Cold chain susceptibility: One of the significant bottlenecks posed by the market is the supply chain vulnerabilities. In this regard, WHO reported that more than 18% of rHGH shipments in Africa failed due to temperature deviations. Besides in the EU's falsified medicines directive raised its logistic costs by 14%, which makes it challenging for manufacturers to invest in this sector. Therefore, the market penetration of products associated with growth hormone deficiency gets fluctuated with the cold chain restraints.
Growth Hormone Deficiency Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.3% |
|
Base Year Market Size (2024) |
USD 4.4 billion |
|
Forecast Year Market Size (2037) |
USD 9.3 billion |
|
Regional Scope |
|
Growth Hormone Deficiency Segmentation
Product (Recombinant Human Growth Hormone, Biosimilars)
Based on product, the recombinant human growth hormone segment is expected to garner the highest share of 58.5% in the growth hormone deficiency market by the end of 2037. The dominance of the segment is possible due to the increased efficacy as approved by the FDA and EMA, and favorable reimbursement policies in the U.S and EU. Besides WHO reports that intensifying competition between biosimilar firms is anticipated to reduce prices by more than 15% thereby increasing access to recombinant growth hormones.
Application (Pediatric GHD, Adult GHD, Turner Syndrome, Prader-Willi Syndrome)
Based on application, the pediatric GHD segment is projected to account for a lucrative share of 47.3% in the growth hormone deficiency market during the forecast period. The segment witnesses such growth due to the safety measures imposed across all nations. In this regard CDC reports that more than 30 countries across the world are mandating neonatal screenings, which drives growth in the pediatric growth hormone deficiency segment. Besides, NIH states that the extensive adoption of telemedicine in remote areas is improving 18% diagnostic rates annually, further fostering expansion of the segment.
Our in-depth analysis of the growth hormone deficiency market includes the following segments:
|
Product |
|
|
Application |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportGrowth Hormone Deficiency Industry– Regional Synopsis
North America Market Analysis
The North America growth hormone deficiency market is poised for growth, with the largest market share of 41.8% by the end of the forecast timeline, growing at a CAGR of 6.4%. The region benefits from increased medical expenditure from Medicare, Medicaid, which cover more than 65.4% of rHGH prescriptions, and enhanced newborn screening procedures. Besides the CDC reports, there is a 26% rise in pediatric GHD diagnoses over the last five years, denoting a positive market outlook. Furthermore, the U.S. FDA approved long-acting therapies such as Skytrofa that remarkably reduce patient dropout rates by 32%.
The Canada market is anticipated to grow at a CAGR of 6.6% owing to the investments by federal and provincial healthcare systems. In this regard, Ontario made a significant investment that is USD 120.5 million for the pediatric oncology program, reflecting positive government support. Besides, Health Canada prioritizes to improve biosimilar adoption, with Alberta to boost the coverage to adult cases. Furthermore, telemedicine proceedings in British Columbia improved diagnosis rates by 23%, vigorously accelerating market expansion.
Asia Pacific Market Statistics
The growth hormone deficiency market in Asia Pacific is gaining traction and is expected to witness the fastest growth during the forecast timeline, rising at a CAGR of 8.2%. The growth in the region is subject to improved adoption of biosimilars and government support for healthcare expansions. The business in the region is further offered by the presence of market leaders in countries such as Japan, India, China, South Korea, and Malaysia. The market in India is expanding with more than 50,00o new pediatric cases in a year. This is the evidence for a wider market scope, fostering a favorable business environment.
China is a global leader in the market, holding a lucrative share of 32.5% in the Asia Pacific market. The country is witnessing such growth due to increased API production and collaborations between its tier 1 hospitals. Besides, NHC states that approximately 1.8 million individuals are diagnosed with growth hormone disorder, which is a 21% increase from 2020, reflecting a positive market demand. Furthermore, nearly USD 1.3 billion was spent on rHGH imports in 2023, readily driving business in the sector.
Companies Dominating the Growth Hormone Deficiency Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The growth hormone deficiency market comprises leading firms that are undertaking various initiatives to strengthen their position in the global market. In this regard, it is reported that leaders such as Novo Nordisk, Pfizer, and Eli Lilly have garnered a significant share of 62%. Besides, firms are leveraging biosimilar expansion, such as those by Pfizer and Sandoz, that reduced prices by 25% to 55% to penetrate emerging nations. Furthermore, long-acting formulations as Novo Nordisk’s weekly injection called NorditropinFlexPro, capture 40% of U.S. new prescriptions, thereby progressing wider market development.
Here is the list of some prominent players in the industry:
|
Company Name |
Country |
Market Share |
|
Novo Nordisk |
Denmark |
30% |
|
Pfizer Inc. |
USA |
20% |
|
Eli Lilly |
USA |
18% |
|
Merck KGaA |
Germany |
10% |
|
Roche |
Switzerland |
9% |
|
Ferring Pharmaceuticals |
Switzerland |
xx% |
|
LG Chem |
South Korea |
xx% |
|
Teva Pharmaceuticals |
Israel |
xx% |
|
Biocon |
India |
xx% |
|
GeneScience Pharmaceuticals |
China |
xx% |
|
Anhui Anke Biotechnology |
China |
xx% |
|
Dong-A ST |
South Korea |
xx% |
|
Mitsubishi Tanabe Pharma |
Japan |
xx% |
|
Lupin |
India |
xx% |
|
Amgen |
USA |
xx% |
|
Sando |
Germany |
xx% |
|
JCR Pharmaceuticals |
Japan |
xx% |
|
CSL Limited |
Australia |
xx% |
|
Malayan Pharmaceuticals |
Malaysia |
xx% |
|
Reliance Life Sciences |
India |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In June 2024, Novo Nordisk announced that the U.S. FDA approved Sogroya for use in children aged 2.5–18 years, expanding from its previous adult-only indication.
- In March 2024, Pfizer Inc. launched NGENLA (somatrogon) in the EU, which is the first long-acting GHD treatment approved for both pediatric and adult use across markets in Europe.
Author Credits: Radhika Pawar
- Report ID: 2683
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
